
Litium (Q3 Review) - Profit Added to Cart

Redeye comments on Litium's Q3 report, which showed solid progress and marked a key milestone with positive EBITDA-CAPEX. ARR growth remained strong, and the Geins acquisition adds a new strategic dimension ahead of 2026. We maintain our Base Case of SEK19 and see continued upside potential as scalability improves.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Litium (Q3 Review) - Profit Added to Cart